BAY 2927088（Sevabertinib）
BAY 2927088（Sevabertinib) is the first non-covalent, potent, oral, selective, and reversible inhibitor of tyrosine kinase that potently inhibits mutant HER2 and mutant EGFR in preclinical models. It targets Exon 20 insertions in non-small-cell lung carcinoma (NSCLC) patients.
| Trivial name | Sevabertinib |
| Catalog Number | E4997 |
| Molecular Formula | C23H23N3O5.HCl |
| CAS# | 2521285-05-0 |
| Inchi | InChI=1S/C23H23N3O5.ClH/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20;/h5-8,27,30H,4,9-11H2,1-3H3;1H/t23-;/m0./s1 |
| Inchi Key | DGHHQBMTXTWTJV-BQAIUKQQSA-N |
| SMILES | CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl |
| Size | 25mg |
| Supplier Page | http://www.selleckchem.com/products/bay-2927088-sevabertinib.html |
| Additional Information | https://file.selleck.cn/downloads/struct/E4997-BAY-2927088-Sevabertinib-chemical-structure.png |